{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-033242","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2024-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.442298+00:00","generated_at":"2026-05-31T20:24:38.951041+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AngioDynamics Q4 pro forma revenue $71.1M; FY2025 outlook $282-288M, share buyback $15M","bullets":["Pro forma Q4 net sales $71.1M (+1.9% YoY); Med Tech +11.3% to $29.3M, Med Device -3.8% to $41.8M.","GAAP net loss per share $0.33; adjusted loss per share $0.05, improving from $0.11 loss a year ago.","FY2025 guidance: net sales $282-288M, Med Tech growth 10-12%, Med Device growth 1-3%, adjusted EPS loss $0.38-0.42.","Board authorized $15M share repurchase program; no long-term debt, $76.1M cash at May 31, 2024.","Received FDA clearance and CE Mark for AlphaVac F18 in pulmonary embolism; settled decade-long IP litigation with BD/Bard."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-033242","json":"https://secwatch.observer/filing/0001140361-24-033242.json","markdown":"https://secwatch.observer/filing/0001140361-24-033242.md","text":"https://secwatch.observer/filing/0001140361-24-033242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124033242/0001140361-24-033242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124033242/ef20032488_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:24:38.951041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}